Search

Bristol-Myers Squibb Co.

Отворен

СекторЗдравеопазване

63.7 -0.59

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

63.12

Максимум

64.41

Ключови измерители

By Trading Economics

Приходи

638M

3.3B

Продажби

1.5B

13B

P/E

Средно за сектора

14.718

56.597

EPS

2.04

Дивидентна доходност

3.69

Марж на печалбата

25.561

Служители

32,500

EBITDA

1.3B

4.9B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+4.26% upside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

3.69%

2.18%

Следващи печалби

29.10.2026 г.

Следваща дата на екс-дивидент

2.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

8.7B

136B

Предишно отваряне

64.29

Предишно затваряне

63.7

Настроения в новините

By Acuity

37%

63%

73 / 339 Класиране в Healthcare

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.09.2026 г., 19:26 ч. UTC

Correlated Moves

Advancing amid favorable market conditions, State Street Health Care ETF rises.

10.09.2026 г., 19:16 ч. UTC

News

Bristol-Myers Squibb shares are lower as HSBC raises price target to $65.00 while maintaining a Hold rating amid ongoing market sentiment.

9.09.2026 г., 23:01 ч. UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, marking a potential rebound after three sessions of declines. No specific news was identified.

8.09.2026 г., 23:06 ч. UTC

Event

Bristol-Myers Squibb Co reported positive Phase 2 trial results for arlocabtagene autoleucel, contributing to shares advancing in after-market trading.

4.09.2026 г., 22:14 ч. UTC

Correlated Moves
Social Media

Bristol-Myers Squibb Co shares are lower in after-market trading following the FDA's withdrawal of Krazati's accelerated approval for colorectal cancer.

3.09.2026 г., 21:51 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, declining since Thursday's close amid a broader market rally and no specific company news.

2.09.2026 г., 23:01 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. Broader market sentiment is affected by rising oil prices amid U.S.-Iran tensions.

1.09.2026 г., 23:06 ч. UTC

Correlated Moves

Bristol-Myers Squibb shares declined after market close, mirroring a broader downturn in the pharmaceutical sector amid rising oil prices and inflation concerns.

31.08.2026 г., 20:07 ч. UTC

News
Social Media
Correlated Moves
Event

Bristol-Myers Squibb shares are higher following positive long-term data on Camzyos presented at the European Society of Cardiology Congress, showing significant patient improvements.

28.08.2026 г., 23:01 ч. UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rebounding from three consecutive lower sessions with no specific news identified.

27.08.2026 г., 19:36 ч. UTC

Bristol-Myers Squibb shares are lower today amid broader market concerns over rising inflation and potential Federal Reserve interest rate hikes.

26.08.2026 г., 23:16 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the decline following a routine session.

25.08.2026 г., 23:21 ч. UTC

Correlated Moves

Bristol-Myers Squibb Co shares are lower in after-market trading, influenced by a decline in the pharmaceutical sector and falling crude oil prices.

24.08.2026 г., 23:41 ч. UTC

Bristol-Myers Squibb shares are trading lower in after-market hours amid weak market conditions and heightened geopolitical tensions affecting overall investor sentiment.

21.08.2026 г., 20:02 ч. UTC

Social Media

Bristol-Myers Squibb Co is higher today following reports of a collaboration with Chai on antibody discovery, enhancing its drug development capabilities.

20.08.2026 г., 20:01 ч. UTC

News

Bristol-Myers Squibb shares are lower amid a significant decline in the Pharmaceuticals sub-sector, despite recent FDA approval for its multiple myeloma drug.

19.08.2026 г., 23:21 ч. UTC

Bristol-Myers Squibb Co shares are higher in after-market hours, fluctuating between a low of -0.28% and a high of 0.50% since Wednesday's close.

18.08.2026 г., 19:46 ч. UTC

Social Media

Bristol-Myers Squibb is using AI tools to cut clinical trial development times, trading higher amid positive market sentiment surrounding these advancements.

17.08.2026 г., 23:01 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market trading amid broader market concerns and unusual selling pressure, though no specific news was identified.

14.08.2026 г., 20:06 ч. UTC

Social Media
News
Event

Bristol-Myers Squibb shares are lower after FDA approval of Zenbexus due to concerns over its $29,500 pricing, which may dampen market sentiment.

13.08.2026 г., 23:56 ч. UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

12.08.2026 г., 23:56 ч. UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

11.08.2026 г., 23:01 ч. UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rising from earlier gains and positioned above their 20-day moving average.

10.08.2026 г., 23:51 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. The decline follows three consecutive sessions of gains amid shifting labor market sentiment.

8.08.2026 г., 00:01 ч. UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, continuing a decline since Friday's close despite being above the 20-day moving average.

7.08.2026 г., 23:06 ч. UTC

Bristol-Myers Squibb shares lower in after-market trading, despite maintaining a position above the 20-day moving average. No specific news was identified.

6.08.2026 г., 23:26 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, influenced by broader market trends and a stronger U.S. Dollar amid rising jobless claims.

5.08.2026 г., 23:01 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. No specific news was identified to explain the movement.

4.08.2026 г., 23:16 ч. UTC

Bristol-Myers Squibb Co. shares gained in after-market trading, reflecting a modest uptick of 0.20% and remaining above their 20-day moving average.

3.08.2026 г., 23:02 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

4.26% нагоре

12-месечна прогноза

Среден 66.833 USD  4.26%

Висок 80 USD

Нисък 40 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

20 ratings

8

Купи

11

Задържане

1

Продай

Настроение

By Acuity

73 / 339 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat